Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Marine natural products: bryostatins in preclinical and clinical studies

P. Kollár, J. Rajchard, Z. Balounová, J. Pazourek,

. 2014 ; 52 (2) : 237-42.

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc14074661

CONTEXT: Bryostatins represent an important group of pharmaceutically promising substances. These compounds are produced by commensal microorganisms naturally occurring in marine invertebrates, mainly in bryozoans. The most frequently investigated substance is bryostatin-1, which is a highly oxygenated macrolide with a polyacetate backbone. OBJECTIVE: The aim of this work was to summarize documented preclinical and clinical effects of bryostatin-class compounds. METHODS: A literature search was made of Medline and Web of Science databases in 2012. RESULTS AND CONCLUSION: Our review showed that bryostatins are potent agonists of protein kinase C. In addition to this, their significant antineoplastic activity against several tumor types has also been established and described. Bryostatin's anticancer activity has been proved against various cancer types. Moreover, significant results have been achieved by using bryostatin-1 in combination with other therapies, including combination with vaccine testing. Concerning other important properties that bryostatins possess, their ability to sensitize some resistant cells to chemotherapy agents, or immunoactivity and further stimulating growth of new neural connections, and enhancing effect on long-term memory are worth mentioning. In particular, some new bryostatin analogs could represent potential therapeutic agent for the treatment of cancer and other diseases in future.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc14074661
003      
CZ-PrNML
005      
20141009121928.0
007      
ta
008      
141006s2014 enk f 000 0|eng||
009      
AR
024    7_
$a 10.3109/13880209.2013.804100 $2 doi
035    __
$a (PubMed)24033119
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Kollár, Peter $u Department of Human Pharmacology and Toxicology, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno , Brno , Czech Republic .
245    10
$a Marine natural products: bryostatins in preclinical and clinical studies / $c P. Kollár, J. Rajchard, Z. Balounová, J. Pazourek,
520    9_
$a CONTEXT: Bryostatins represent an important group of pharmaceutically promising substances. These compounds are produced by commensal microorganisms naturally occurring in marine invertebrates, mainly in bryozoans. The most frequently investigated substance is bryostatin-1, which is a highly oxygenated macrolide with a polyacetate backbone. OBJECTIVE: The aim of this work was to summarize documented preclinical and clinical effects of bryostatin-class compounds. METHODS: A literature search was made of Medline and Web of Science databases in 2012. RESULTS AND CONCLUSION: Our review showed that bryostatins are potent agonists of protein kinase C. In addition to this, their significant antineoplastic activity against several tumor types has also been established and described. Bryostatin's anticancer activity has been proved against various cancer types. Moreover, significant results have been achieved by using bryostatin-1 in combination with other therapies, including combination with vaccine testing. Concerning other important properties that bryostatins possess, their ability to sensitize some resistant cells to chemotherapy agents, or immunoactivity and further stimulating growth of new neural connections, and enhancing effect on long-term memory are worth mentioning. In particular, some new bryostatin analogs could represent potential therapeutic agent for the treatment of cancer and other diseases in future.
650    _2
$a zvířata $7 D000818
650    _2
$a protinádorové látky $x chemie $x farmakologie $7 D000970
650    _2
$a vodní organismy $x metabolismus $7 D059001
650    _2
$a biologické přípravky $x chemie $x farmakologie $7 D001688
650    _2
$a bryostatiny $x chemie $x farmakologie $7 D054713
650    _2
$a klinické zkoušky jako téma $7 D002986
650    _2
$a preklinické hodnocení léčiv $7 D004353
650    _2
$a lidé $7 D006801
650    _2
$a bezobratlí $x metabolismus $7 D007448
650    _2
$a nádory $x farmakoterapie $x patologie $7 D009369
650    _2
$a proteinkinasa C $x účinky léků $x metabolismus $7 D011493
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Rajchard, Josef
700    1_
$a Balounová, Zuzana
700    1_
$a Pazourek, Jiří
773    0_
$w MED00005335 $t Pharmaceutical biology $x 1744-5116 $g Roč. 52, č. 2 (2014), s. 237-42
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24033119 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20141006 $b ABA008
991    __
$a 20141009122316 $b ABA008
999    __
$a ok $b bmc $g 1042544 $s 873573
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 52 $c 2 $d 237-42 $i 1744-5116 $m Pharmaceutical biology $n Pharm. biol. $x MED00005335
LZP    __
$a Pubmed-20141006

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...